We use cookies to improve your experience and for marketing. Read our cookie policy or manage cookies.
OpenAI CEO Sam Altman turned down a $97.4 billion acquisition bid from Elon Musk and others, citing plans to stay independent and expand, sparking further debate in tech circles.
Watts Water Technologies reported impressive Q4 2024 results, exceeding market expectations with strategic growth and profitability, solidifying its industry-leading position.
Simpson Manufacturing Co. exceeds Q4 revenue expectations with a 3.1% increase, showcasing resilience and growth potential despite industry challenges.
Fluence Energy faces a 48.7% revenue drop in Q4 CY2024 despite strong lithium-ion market growth. The company remains optimistic with a $5.1 billion backlog and strategies to improve future results.
Medpace Holdings exceeded Q4 earnings expectations, showcasing robust profitability despite falling short on full-year guidance. Explore their financial performance and future market potential.
Inspire Medical Systems surpasses Q4 revenue expectations with 24.5% growth, driven by its neurostimulation system for obstructive sleep apnea, highlighting strong financial performance and market demand.
Amkor Technology reports a 7% decline in Q4 sales, missing revenue forecasts. Despite challenges in automotive and industrial markets, growth in AI and ARM-based PCs provides a glimmer of hope for future expansion.
Learn why U.S. container imports are expected to stay high as shippers work to pre-empt tariffs on China, with projections of continued growth in TEU volumes through 2025.
Lattice Semiconductor aligns with revenue expectations in Q4 2024 despite a 31.2% sales drop, focusing on growth in 5G, IoT, and AI sectors.
Columbus McKinnon's Q4 performance missed expectations, facing industrial machinery sector challenges with a focus on emerging trends and efficiencies.
Leading beauty company Coty reported lower-than-expected Q2 revenues due to reduced demand in the U.S. cosmetics market.
Vertex Pharmaceuticals projects a notable revenue increase by leveraging its cystic fibrosis treatments and new pain management medication, Journavx, with plans for future growth.
122
